Logo image of SYRS

SYROS PHARMACEUTICALS INC (SYRS) Stock Fundamental Analysis

NASDAQ:SYRS - Nasdaq - US87184Q2066 - Common Stock - Currency: USD

0.1743  0 (-0.85%)

After market: 0.1748 +0 (+0.29%)

Fundamental Rating

1

Taking everything into account, SYRS scores 1 out of 10 in our fundamental rating. SYRS was compared to 572 industry peers in the Biotechnology industry. SYRS has a bad profitability rating. Also its financial health evaluation is rather negative. SYRS does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

SYRS had negative earnings in the past year.
In the past year SYRS has reported a negative cash flow from operations.
SYRS had negative earnings in each of the past 5 years.
SYRS had a negative operating cash flow in each of the past 5 years.
SYRS Yearly Net Income VS EBIT VS OCF VS FCFSYRS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of -115.08%, SYRS is doing worse than 79.40% of the companies in the same industry.
Industry RankSector Rank
ROA -115.08%
ROE N/A
ROIC N/A
ROA(3y)-61.3%
ROA(5y)-54.72%
ROE(3y)-387.81%
ROE(5y)-270.29%
ROIC(3y)N/A
ROIC(5y)N/A
SYRS Yearly ROA, ROE, ROICSYRS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SYRS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SYRS Yearly Profit, Operating, Gross MarginsSYRS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

2

2. Health

2.1 Basic Checks

SYRS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SYRS has been increased compared to 1 year ago.
Compared to 5 years ago, SYRS has more shares outstanding
The debt/assets ratio for SYRS is higher compared to a year ago.
SYRS Yearly Shares OutstandingSYRS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
SYRS Yearly Total Debt VS Total AssetsSYRS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -16.25, we must say that SYRS is in the distress zone and has some risk of bankruptcy.
SYRS has a worse Altman-Z score (-16.25) than 84.01% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -16.25
ROIC/WACCN/A
WACC9.52%
SYRS Yearly LT Debt VS Equity VS FCFSYRS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M -100M

2.3 Liquidity

SYRS has a Current Ratio of 2.25. This indicates that SYRS is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.25, SYRS is not doing good in the industry: 74.42% of the companies in the same industry are doing better.
SYRS has a Quick Ratio of 2.25. This indicates that SYRS is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.25, SYRS is not doing good in the industry: 72.82% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.25
Quick Ratio 2.25
SYRS Yearly Current Assets VS Current LiabilitesSYRS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.20% over the past year.
Looking at the last year, SYRS shows a very negative growth in Revenue. The Revenue has decreased by -95.61% in the last year.
SYRS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.12% yearly.
EPS 1Y (TTM)19.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.81%
Revenue 1Y (TTM)-95.61%
Revenue growth 3Y-13%
Revenue growth 5Y37.12%
Sales Q2Q%-100%

3.2 Future

SYRS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.05% yearly.
The Revenue is expected to decrease by -32.07% on average over the next years. This is quite bad
EPS Next Y72.08%
EPS Next 2Y26.16%
EPS Next 3Y19.34%
EPS Next 5Y7.05%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y37.58%
Revenue Next 5Y-32.07%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
SYRS Yearly Revenue VS EstimatesSYRS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20M 40M 60M 80M
SYRS Yearly EPS VS EstimatesSYRS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SYRS. In the last year negative earnings were reported.
Also next year SYRS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SYRS Price Earnings VS Forward Price EarningsSYRS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SYRS Per share dataSYRS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as SYRS's earnings are expected to grow with 19.34% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.16%
EPS Next 3Y19.34%

More info and screens

0

5. Dividend

5.1 Amount

SYRS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SYROS PHARMACEUTICALS INC

NASDAQ:SYRS (2/21/2025, 8:00:01 PM)

After market: 0.1748 +0 (+0.29%)

0.1743

0 (-0.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-31 2024-10-31/bmo
Earnings (Next)03-06 2025-03-06/amc
Inst Owners24.37%
Inst Owner Change-97.64%
Ins Owners0.78%
Ins Owner Change-3.21%
Market Cap4.68M
Analysts77.78
Price Target10.71 (6044.58%)
Short Float %2.74%
Short Ratio0.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)51.44%
Min EPS beat(2)24.66%
Max EPS beat(2)78.21%
EPS beat(4)3
Avg EPS beat(4)26.22%
Min EPS beat(4)-86.73%
Max EPS beat(4)88.72%
EPS beat(8)5
Avg EPS beat(8)22.54%
EPS beat(12)8
Avg EPS beat(12)17.39%
EPS beat(16)11
Avg EPS beat(16)15.77%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-95.26%
Min Revenue beat(4)-100%
Max Revenue beat(4)-81.03%
Revenue beat(8)0
Avg Revenue beat(8)-67.21%
Revenue beat(12)3
Avg Revenue beat(12)-38.68%
Revenue beat(16)7
Avg Revenue beat(16)-14.54%
PT rev (1m)0%
PT rev (3m)-4.55%
EPS NQ rev (1m)-3.21%
EPS NQ rev (3m)0.76%
EPS NY rev (1m)-1.72%
EPS NY rev (3m)-0.17%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.12
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.03
EYN/A
EPS(NY)-2.35
Fwd EYN/A
FCF(TTM)-3.73
FCFYN/A
OCF(TTM)-3.73
OCFYN/A
SpS0.01
BVpS-0.41
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -115.08%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.3%
ROA(5y)-54.72%
ROE(3y)-387.81%
ROE(5y)-270.29%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score0
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.25
Quick Ratio 2.25
Altman-Z -16.25
F-Score0
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)31.74%
Cap/Depr(5y)133.96%
Cap/Sales(3y)5.46%
Cap/Sales(5y)135.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.81%
EPS Next Y72.08%
EPS Next 2Y26.16%
EPS Next 3Y19.34%
EPS Next 5Y7.05%
Revenue 1Y (TTM)-95.61%
Revenue growth 3Y-13%
Revenue growth 5Y37.12%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y37.58%
Revenue Next 5Y-32.07%
EBIT growth 1Y17.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13%
OCF growth 3YN/A
OCF growth 5YN/A